Abpro provides pipeline update; Celltrion partnership for ABP-102 fully funded with up to $1.75B milestones

Abpro Holdings, Inc.

Celltrion funds all development of ABP-102 (HER2/CD3 T-cell engager) for breast/gastric cancer; Abpro retains 50% profit share.
ABP-201 (VEGF/ANG2) for Wet AMD/DME: IND filing expected Q1 2026, Phase 1 start same year.
ABP-102 IND filing targeted for 2H 2025; Phase 1 initiation in 1H 2026.
Additional pipeline: ABP-150 (Claudin18.2/CD3) and ABP-110 (GPC3/CD3) IND filings in 2026, Phase 1 in 2027.
No financial results; presentation highlights platform, preclinical data, and upcoming milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.